Navigation Links
Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
Date:5/9/2011

SAN DIEGO, May 9, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishments and financial results for the first quarter ended March 31, 2011.

"Results from our recently completed Phase 2b study of lesinurad in combination with allopurinol demonstrate lesinurad's potential to bring relief to millions of patients currently suffering with gout," commented Barry D. Quart, PharmD, Ardea's president and chief executive officer.  "We look forward to presenting additional results from this study at the Annual European Congress of Rheumatology in May and discussing our plans for Phase 3 with the Food and Drug Administration in the third quarter."

Recent Accomplishments and Important Upcoming Events

  • In January 2011, we announced positive, topline results from a Phase 2b study (Study 203) adding lesinurad to allopurinol in 208 allopurinol-refractory patients.  At the highest lesinurad dose tested in this study, the number of patients taking the combination who achieved the medically recommended target of below 6 mg/dL was more than three times the number of patients who achieved the target on allopurinol alone.  This translated into an overall response rate of 89 percent using a "last observation carried forward", or LOCF, analysis.  The combination of lesinurad and allopurinol was also well tolerated.
  • In February 2011, we completed an underwritten public offering of approximately 3.2 million shares of our common stock, including the full exercise of an overallotment option granted to the underwriters.  Net proceeds from the sale of the shares, after deducting underwriting discounts and commissions and offering expenses, were approximately $78.1 million.
  • I
    '/>"/>

  • SOURCE Ardea Biosciences, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
    2. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
    3. Ardea Biosciences Prices Public Offering of Common Stock
    4. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
    5. Ardea Biosciences to Present at Two Upcoming Investor Conferences
    6. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
    7. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
    8. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
    9. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
    10. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
    11. Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2014)... San Francisco, California (PRWEB) July 28, 2014 ... reach USD 604.40 billion by 2020, according to a ... scope coupled with the rising demand for effective vaccines ... to patients with unmet medical needs is expected to ... addition, the need to enhance agricultural productivity via the ...
    (Date:7/28/2014)... IN (PRWEB) July 28, 2014 The ... Center, in Muncie IN, is pleased to announce that ... the National Museum of the United States Air Force. ... a year-long process that concluded this spring with an ... the Dayton, OH museum. , The National Museum ...
    (Date:7/25/2014)... Trillions of bacteria live in each person,s digestive tract. ... food and stave off harmful infections, but their role ... help shed light on the role of these bacteria, ... Eric Alm recently tracked fluctuations in the bacterial populations ... findings, described in the July 25 issue of the ...
    (Date:7/25/2014)... (PRWEB) July 25, 2014 WABC Radio show ... Pet with Lorry Young will be hosting California-based Vet-Stem, ... about stem cell therapy in pets. Dr. Harman first ... of stem cell therapy for pets suffering from osteoarthritis and ... Regenerative Veterinary Medicine industry forward. , Young has invited Dr. ...
    Breaking Biology Technology:Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4AMA’s National Model Aviation Museum Granted Full Civilian Museum Certification by the National Museum of the United States Air Force 2Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3
    ... compounds with multiple new and existing antibiotics to create ... ... SAN DIEGO and LONDON, June 16 Mpex Pharmaceuticals ... strategic alliance for the discovery, development and,commercialization of novel medicines ...
    ... encourage early diagnosis of dementia ... and participation in clinical trials., Silicon ... the Internet to Transform Medical Research and ... and The University of,California, San Francisco (UCSF) today launched ...
    ... Planned to Initiate This Summer, SOUTH SAN ... EXEL ) announced today that the company and ... agreement on the phase 3,registration trial of XL184, ... VEGFR2, via the Special Protocol Assessment process. Exelixis,has ...
    Cached Biology Technology:GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections 2GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections 3GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections 4GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections 5UCSF and YouTube Launch Channel Dedicated to Educating the Public About Neurodegenerative Diseases 2UCSF and YouTube Launch Channel Dedicated to Educating the Public About Neurodegenerative Diseases 3Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 2Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 3Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 4Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 5
    (Date:7/25/2014)... (SB) is a complex congenital central nervous system ... of the neural tubes during the embryonic phase. ... and fecal incontinence and neurocognitive retardation. Such problems ... of life. Researchers at Ankara Physical Medicine and ... functional performance in children with SB, using the ...
    (Date:7/25/2014)... molecular testing panel developed at UPMC greatly increases ... for patients with thyroid nodules and cancer, report ... (UPCI), partner with UPMC CancerCenter., The test, available ... diagnostic testing agencies, improved the chances of patients ... according to the study published this month in ...
    (Date:7/24/2014)... leads to conflict among people around the world, a ... Health & Ecosystems: Analysis of Linkages (HEAL) Program Director ... tackle global biodiversity decline. , The harvest of wild ... and provides protein for more than a billion of ... that today,s unprecedented loss of wildlife, is bringing with ...
    Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3New study draws links between wildlife loss and social conflicts 2
    ... far-fetched to some, but for those with arousal system disturbances ... idea that they could sense they were really outside their ... 13,000 Europeans, almost 6 percent said they have had such ... team at the University of Kentucky have studied the link ...
    ... and geographic data of the H5N1 avian flu virus ... found that multiple strains of the virus originated in ... of the migration routes through which the strains spread ... develop and migrate, health officials can better limit the ...
    ... have discovered a factor that controls blood sugar's manufacture ... its building blocks. The findings are reported in the ... Cell Press. , The study found that mice deficient ... of transcription factors, become severely lacking in the blood ...
    Cached Biology News:Out-of-body experiences may be caused by arousal system disturbances in brain 2UCI scientists reconstruct migration of avian flu virus 2Blood sugar's manufacture limited by building blocks' supply 2
    Size & Applications: 100 ul (2 mM). Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.) Storage Temp.: -20C Shelf Life: 6-12 month...
    NM522 contains an F episome, which is required for production of ssDNA and for blue/white color selection. To maintain the F, NM522 should be grown on minimal (M-9) medium....
    Request Info...
    ...
    Biology Products: